LPA-Induced Thromboxane A2-Mediated Vasoconstriction Is Limited to Poly-Unsaturated Molecular Species in Mouse Aortas
Open Access
- 22 June 2024
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (13) , 6872
Abstract
We have previously reported that, in aortic rings, 18:1 lysophosphatidic acid (LPA) can induce both vasodilation and vasoconstriction depending on the integrity of the endothelium. The predominant molecular species generated in blood serum are poly-unsaturated LPA species, yet the vascular effects of these species are largely unexplored. We aimed to compare the vasoactive effects of seven naturally occurring LPA species in order to elucidate their potential pathophysiological role in vasculopathies. Vascular tone was measured using myography, and thromboxane A2 (TXA2) release was detected by ELISA in C57Bl/6 mouse aortas. The Ca2+-responses to LPA-stimulated primary isolated endothelial cells were measured by Fluo-4 AM imaging. Our results indicate that saturated molecular species of LPA elicit no significant effect on the vascular tone of the aorta. In contrast, all 18 unsaturated carbon-containing (C18) LPAs (18:1, 18:2, 18:3) were effective, with 18:1 LPA being the most potent. However, following inhibition of cyclooxygenase (COX), these LPAs induced similar vasorelaxation, primarily indicating that the vasoconstrictor potency differed among these species. Indeed, C18 LPA evoked a similar Ca2+-signal in endothelial cells, whereas in endothelium-denuded aortas, the constrictor activity increased with the level of unsaturation, correlating with TXA2 release in intact aortas. COX inhibition abolished TXA2 release, and the C18 LPA induced vasoconstriction. In conclusion, polyunsaturated LPA have markedly increased TXA2-releasing and vasoconstrictor capacity, implying potential pathophysiological consequences in vasculopathies.Keywords
Funding Information
- Hungarian National Research, Development, and Innovation Office (K-125174, PD-132851, K-135683, K-139230, NVKP_16-1-2016-0042, EFOP-3.6.3-VEKOP-16-2017-00009, 2020-1.1.6-JÖVŐ-2021-00010, 2020-1.1.6-JÖVŐ-2021-00013, TKP2021-EGA-25, ÚNKP-23-4-I-SE-17)
- Ministry for Innovation and Technology from the Hungarian NRDI Fund (K-125174, PD-132851, K-135683, K-139230, NVKP_16-1-2016-0042, EFOP-3.6.3-VEKOP-16-2017-00009, 2020-1.1.6-JÖVŐ-2021-00010, 2020-1.1.6-JÖVŐ-2021-00013, TKP2021-EGA-25, ÚNKP-23-4-I-SE-17)
- National Research, Development and Innovation Fund (K-125174, PD-132851, K-135683, K-139230, NVKP_16-1-2016-0042, EFOP-3.6.3-VEKOP-16-2017-00009, 2020-1.1.6-JÖVŐ-2021-00010, 2020-1.1.6-JÖVŐ-2021-00013, TKP2021-EGA-25, ÚNKP-23-4-I-SE-17)
This publication has 39 references indexed in Scilit:
- Nitric oxide signaling in health and diseaseCell, 2022
- Suppressing postcollection lysophosphatidic acid metabolism improves the precision of plasma LPA quantificationJournal of Lipid Research, 2021
- Lysophosphatidic Acid Signalling in Nervous System Development and FunctionNeuroMolecular Medicine, 2020
- Roles for lysophosphatidic acid signaling in vascular development and diseaseBiochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 2020
- A Novel Agonist of the Type 1 Lysophosphatidic Acid Receptor (LPA1), UCM-05194, Shows Efficacy in Neuropathic Pain AmeliorationJournal of Medicinal Chemistry, 2019
- Lysophosphatidic acid and its receptors: pharmacology and therapeutic potential in atherosclerosis and vascular diseasePharmacology & Therapeutics, 2019
- Increased circulating plasma lysophosphatidic acid in patients with acute coronary syndromeClinica Chimica Acta, 2012
- Lysophosphatidic acid-induced arterial wall remodeling: Requirement of PPARγ but not LPA1 or LPA2 GPCRCellular Signalling, 2009
- Direct Quantitative Analysis of Lysophosphatidic Acid Molecular Species by Stable Isotope Dilution Electrospray Ionization Liquid Chromatography–Mass SpectrometryAnalytical Biochemistry, 2001
- Lysophosphatidic acid (LPA) receptors of the EDG family are differentially activated by LPA speciesFEBS Letters, 2000